Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.75 Consensus Price Target from Brokerages

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.75.

AUTL has been the subject of several analyst reports. Mizuho cut their price target on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. HC Wainwright boosted their target price on Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Zacks Research upgraded Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Finally, Weiss Ratings lowered Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 14th.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors have recently modified their holdings of the stock. Marex Group plc bought a new position in shares of Autolus Therapeutics in the second quarter worth about $28,000. Independent Advisor Alliance bought a new position in shares of Autolus Therapeutics in the fourth quarter worth about $28,000. SmartHarvest Portfolios LLC bought a new position in shares of Autolus Therapeutics in the fourth quarter worth about $43,000. Waverly Advisors LLC bought a new position in shares of Autolus Therapeutics in the first quarter worth about $37,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Autolus Therapeutics in the third quarter worth about $46,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Stock Performance

NASDAQ:AUTL opened at $1.70 on Monday. The company has a 50-day moving average of $1.50 and a 200-day moving average of $1.52. The company has a market capitalization of $452.44 million, a price-to-earnings ratio of -1.56 and a beta of 1.93. Autolus Therapeutics has a 52 week low of $1.18 and a 52 week high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. The company had revenue of $26.22 million during the quarter, compared to the consensus estimate of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. Sell-side analysts forecast that Autolus Therapeutics will post -0.97 EPS for the current year.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.